ASOPRS 2021

We recently spoke with Andrea Lora Kossler, MD, FACS, from the Byers Eye Institute at Stanford University about results from the study “Effect of Teprotumumab on Ocular Surface Disease in Active Thyroid Eye Disease,” which she...

Physician’s Weekly spoke recently with Roman Shinder, MD, FACS, from the Departments of Ophthalmology and Otolaryngology at SUNY Downstate Medical Center, about study results he and his colleague, Anna Artymowicz, MD, presented...

The effects of teprotumumab on volume of lacrimal glands and tear production were presented at ASOPRS 2021. Dry eye syndrome is a common cause of discomfort among individuals with thyroid eye disease and can occur in up to 85%...

While phase II and III trials indicate that teprotumumab therapy can significantly reduce proptosis and Clinical Activity Score (CAS) in patients with recent-onset (< 8 months), untreated TED (except for steroid therapy >...

Past research has found that lacrimal gland (LG) enlargement can occur in thyroid eye disease (TED) secondary to antibody-mediated inflammation. However, studies specifically quantified LG volume in TED patients with compressive...

New research presented at the American Society of Ophthalmic Plastic & Reconstructive Surgery’s fall symposium highlighted the benefits of Tepezza (teprotumumab) for patients with thyroid eye and Graves disease....